| Immune-related adverse events with immune checkpoint blockade: a comprehensive review JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ... European journal of cancer 54, 139-148, 2016 | 2235 | 2016 |
| Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ... Clinical Cancer Research 23 (8), 1920-1928, 2017 | 1281 | 2017 |
| A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ... The Lancet Oncology 19 (9), 1180-1191, 2018 | 1064 | 2018 |
| Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study T Powles, PH O'Donnell, C Massard, HT Arkenau, TW Friedlander, ... JAMA oncology 3 (9), e172411-e172411, 2017 | 942 | 2017 |
| Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer C Massard, MS Gordon, S Sharma, S Rafii, ZA Wainberg, J Luke, ... Journal of Clinical Oncology 34 (26), 3119-3125, 2016 | 934 | 2016 |
| High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ... Cancer discovery 7 (6), 586-595, 2017 | 734 | 2017 |
| Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study DF McDermott, JA Sosman, M Sznol, C Massard, MS Gordon, O Hamid, ... Journal of Clinical Oncology 34 (8), 833-842, 2016 | 609 | 2016 |
| A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas F Farace, C Massard, N Vimond, F Drusch, N Jacques, F Billiot, ... British journal of cancer 105 (6), 847-853, 2011 | 483 | 2011 |
| Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Y Loriot, D Bianchini, E Ileana, S Sandhu, A Patrikidou, C Pezaro, ... Annals of oncology 24 (7), 1807-1812, 2013 | 425 | 2013 |
| Mutational profile of metastatic breast cancers: a retrospective analysis C Lefebvre, T Bachelot, T Filleron, M Pedrero, M Campone, JC Soria, ... PLoS medicine 13 (12), e1002201, 2016 | 396 | 2016 |
| Hyperprogressive disease: recognizing a novel pattern to improve patient management S Champiat, R Ferrara, C Massard, B Besse, A Marabelle, JC Soria, ... Nature reviews Clinical oncology 15 (12), 748-762, 2018 | 395 | 2018 |
| VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management H Izzedine, C Massard, JP Spano, F Goldwasser, D Khayat, JC Soria European Journal of Cancer 46 (2), 439-448, 2010 | 388 | 2010 |
| Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study AR Hansen, C Massard, PA Ott, NB Haas, JS Lopez, S Ejadi, ... Annals of oncology 29 (8), 1807-1813, 2018 | 361 | 2018 |
| Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer A Simonaggio, JM Michot, AL Voisin, J Le Pavec, M Collins, A Lallart, ... JAMA oncology 5 (9), 1310-1317, 2019 | 346 | 2019 |
| Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss JS de Bono, U De Giorgi, DN Rodrigues, C Massard, S Bracarda, A Font, ... Clinical Cancer Research 25 (3), 928-936, 2019 | 317 | 2019 |
| Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy International Prognostic Factors Study Group Journal of Clinical Oncology 28 (33), 4906-4911, 2010 | 308 | 2010 |
| Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease FX Danlos, AL Voisin, V Dyevre, JM Michot, E Routier, L Taillade, ... European Journal of Cancer 91, 21-29, 2018 | 293 | 2018 |
| Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial C Sweeney, S Bracarda, CN Sternberg, KN Chi, D Olmos, S Sandhu, ... The Lancet 398 (10295), 131-142, 2021 | 271 | 2021 |
| Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database A Lorch, C Bascoul-Mollevi, A Kramar, L Einhorn, A Necchi, C Massard, ... Journal of clinical oncology 29 (16), 2178-2184, 2011 | 268 | 2011 |
| Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors J Lewin, JC Soria, A Stathis, JP Delord, S Peters, A Awada, PG Aftimos, ... Journal of Clinical Oncology 36 (30), 3007-3014, 2018 | 267 | 2018 |
Jean-Charles SoriaAmgen R&DVerified email at amgen.com
